Health Trials

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

ConditionRefractory Autoimmune Diseases
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

About this trial

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.

Eligibility criteria

Qualifiers

None

Disqualifiers

SLE population:.

IIM population:.

SSc population:.

RA population:.

Trial design

Treatments tested in this trial

  • BMS-986515
  • Fludarabine
  • Cyclophosphamide
  • Tocilizumab

Treatment groups

125 Participants
are divided into 1 treatment group

Sponsors and collaborators

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Lead sponsor

Source ClinicalTrials.gov